This application note presents a groundbreaking approach to addressing the challenges of identifying conserved, neutralizing epitopes for effective antibody therapeutics against emerging coronavirus variants. Leveraging multiplexed antigen screening and single-cell immune profiling technology, over 9,000 fully human CoV-specific antibodies were identified, paving the way for potential pan-coronavirus vaccine candidates. The manuscript also introduces Twist High Throughput Antibody (HT IgG) production, a gene-to-protein workflow designed to overcome the bottleneck of antibody synthesis, expression, and purification at scale, enabling rapid screening of hundreds or thousands of leads for biophysical and pharmacokinetic properties.